Halozyme Therapeutics, Inc.
HALO
株式のランク
#1547
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San... Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
株価
$123.84
最終同期: 2026-10-20
時価総額
$14.06B
変化（1日）
1.09%
変化（1年）
85.17%
国
US
取引 Halozyme Therapeutics, Inc. (HALO)
カテゴリー
Healthcare
Halozyme Therapeutics, Inc.（HALO）の利益
Jun 2026 時点の利益 TTM: $583.34M
Halozyme Therapeutics, Inc. の最新の財務報告によると、同社の現在の利益は $583.34M です。2023 年には $348.33M の利益を上げ、これは 2022 年の利益 $248.92M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Halozyme Therapeutics, Inc. の利益の推移（2001 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $583.34M | 4.70% |
| 2024 | $557.13M | 59.94% |
| 2023 | $348.33M | 39.94% |
| 2022 | $248.92M | 0.16% |
| 2021 | $248.52M | 92.20% |
| 2020 | $129.30M | -278.96% |
| 2019 | $-72.25M | -9.45% |
| 2018 | $-79.79M | -229.51% |
| 2017 | $61.61M | -160.48% |
| 2016 | $-101.86M | 216.03% |
| 2015 | $-32.23M | -52.86% |
| 2014 | $-68.38M | -18.09% |
| 2013 | $-83.48M | 55.88% |
| 2012 | $-53.55M | -99.73% |
| 2011 | $-19.77B | 37,032.30% |
| 2010 | $-53.24M | -8.77% |
| 2009 | $-58.36M | 19.79% |
| 2008 | $-48.72M | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | -100.00% |
| 2005 | $-13.28M | 46.02% |
| 2004 | $-9.09M | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $-64.46K | 62.57% |
| 2001 | $-39.65K | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | 804.26% |
US
|
|
| $-3.09B | -629.20% |
US
|
|
| $-4.02B | -788.49% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 234.39% |
NL
|
